BioLife SolutionsBLFS -0.18%72 Debt-to-Equity is 0.04 as of Mar. 2026, which is 43% below its 10-year median of 0.07. GuruFocus rates BLFS with a GF Score™ of 72/100 and a GF Value™ of $28.78 (Fairly Valued). The stock has 5 warning signs investors should review. Among 704 Medical Devices & Instruments companies, BioLife Solutions ranks better than 85.51% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for BioLife Solutions's Debt-to-Equity or its related term are showing as below:
BLFS'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.07 Max: 1.4
Current: 0.04
During the past 13 years, the highest Debt-to-Equity Ratio of BioLife Solutions was 1.40. The lowest was 0.00. And the median was 0.07.
BLFS's Debt-to-Equity is ranked better than 85.51% of 704
companies
in the Medical Devices & Instruments industry
Industry Median: 0.225
vs BLFS: 0.04
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
BioLife Solutions Debt-to-Equity Related Terms
BioLife Solutions Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for BioLife Solutions's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLFS vs STAA, ATRC, KMTS: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, BioLife Solutions's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLife Solutions Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where BioLife Solutions's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLife Solutions (BLFS) has a Debt-to-Equity of 0.04 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BioLife Solutions and its competitors. This is 43% below median its historical median of 0.07. According to the industry distribution chart, BioLife Solutions ranks #102 out of 704 companies in the Medical Devices & Instruments industry, placing it in the top 14.5%.
Is BioLife Solutions' Debt-to-Equity too high?
BioLife Solutions' current Debt-to-Equity of 0.04 is 43% below median its 10-year median of 0.07. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. BioLife Solutions' value of 0.04 is 82.2% below this industry median. Based on the distribution chart, BioLife Solutions ranks #102 out of 704 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, BioLife Solutions has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' Debt-to-Equity compare to STAA and ATRC?
According to the Medical Devices & Instruments industry distribution chart, BioLife Solutions ranks #102 out of 704 companies for Debt-to-Equity. This places BioLife Solutions in the top 15% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.23. BioLife Solutions' value of 0.04 is 82.2% below this benchmark. While the company's 10-year median is 0.07 vs. the industry median of 0.23, BioLife Solutions has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLife Solutions's current Debt-to-Equity of 0.04 is 82.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BioLife Solutions and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLife Solutions's current Debt-to-Equity is 0.04, which is 43% below median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Fairly Valued. The stock's GF Value™ is $28.78, compared to a current price of $28.18 — trading 2.1% below its estimated fair value. The current Debt-to-Equity is 0.04, which is 43% below median its 10-year median of 0.07 and 82.2% below the Medical Devices & Instruments industry median of 0.23. BioLife Solutions' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current Debt-to-Equity is 0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioLife Solutions (BLFS) Overvalued in 2026?
Based on GuruFocus' analysis, BioLife Solutions stock appears to be undervalued.
The current stock price of $28.18 is trading 2.1% below its estimated GF Value™ of $28.78.
GuruFocus considers BioLife Solutions to be Fairly Valued.
Key valuation signals for BLFS:
Debt-to-Equity: 0.04 (43% below median its 10-year median of 0.07)
GF Value™: $28.78 vs. price of $28.18 (2.1% below fair value)
Industry Position: 82.2% below the Medical Devices & Instruments median (#102 of 704)
No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
72GF Score
Get the complete analysis for BLFS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLFS has been successfully added to your 
